


Status: Currently Official on 14-Feb-2025
Official Date: Official as of 01-May-2020
Document Type: USP Monographs
DocId: GUID-E9494226-4AAE-4175-8102-61063DE91202_2_en-US
DOI: https://doi.org/10.31003/USPNF_M39908_02_01
DOI Ref: fbs6d

© 2025 USPC
Do not distribute

Ibutilide Fumarate



$(C_{20}H_{36}N_2O_3S)_2 \cdot C_4H_4O_4$ 885.23

Methanesulfonamide, *N*-[4-[4-(ethylheptylamino)-1-hydroxybutyl]phenyl]-, (\pm)-, (*E*)-2-butenedioate (2:1) (salt);

(\pm)-4-[4-(ethylheptylamino)-1-hydroxybutyl]methanesulfonanilide fumarate (2:1) (salt) CAS RN[®]: 122647-32-9; UNII: 9L5X4M5L6I.

Ibutilide free base CAS RN[®]: 122647-31-8; UNII: 2436VX1U9B.

DEFINITION

Ibutilide Fumarate contains NLT 98.0% and NMT 102.0% of ibutilide fumarate $[(C_{20}H_{36}N_2O_3S)_2 \cdot C_4H_4O_4]$, calculated on the anhydrous basis.

IDENTIFICATION

Change to read:

- A. [▲][SPECTROSCOPIC IDENTIFICATION TESTS \(197\), Infrared Spectroscopy: 197K](#) [▲] (CN 1-MAY-2020)
- B. The retention time of the major peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the Assay.

ASSAY

• PROCEDURE

Solution A: 2 mL/L of triethylamine in water. Adjust with perchloric acid to a pH of 2.5.

Mobile phase: Acetonitrile and *Solution A* (40:60)

Standard solution: 0.2 mg/mL of [USP Ibutilide Fumarate RS](#) in *Mobile phase*. [NOTE—Sonication may be necessary for complete dissolution.]

Sample solution: 0.2 mg/mL of Ibutilide Fumarate in *Mobile phase*. [NOTE—Sonication may be necessary for complete dissolution.]

Chromatographic system

(See [Chromatography \(621\), System Suitability](#).)

Mode: LC

Detector: UV 227 nm

Column: 4.6-mm \times 25-cm; 5- μ m packing L1

Column temperature: 30°

Flow rate: 1 mL/min

Injection volume: 20 μ L

Run time: NLT 3 times the retention time of the ibutilide peak

System suitability

Sample: *Standard solution*

Suitability requirements

Tailing factor: NMT 2

Relative standard deviation: NMT 0.73%

Analysis

Samples: *Standard solution* and *Sample solution*

Calculate the percentage of ibutilide fumarate $[(C_{20}H_{36}N_2O_3S)_2 \cdot C_4H_4O_4]$ in the portion of Ibutilide Fumarate taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

r_U = peak response of ibutilide from the *Sample solution*

r_S = peak response of ibutilide from the *Standard solution*

C_S = concentration of [USP Ibutilide Fumarate RS](#) in the *Standard solution* (mg/mL)

C_U = concentration of Ibutilide Fumarate in the *Sample solution* (mg/mL)**Acceptance criteria:** 98.0%–102.0% on the anhydrous basis**IMPURITIES**

- **RESIDUE ON IGNITION (281):** NMT 0.20%

CONTENT OF FUMARIC ACID**Solution A, Mobile phase, and Sample solution:** Proceed as directed in the Assay.**Chromatographic system:** Proceed as directed in the Assay, except use a UV detector at 207 nm.**Standard stock solution:** 0.2 mg/mL of [USP Fumaric Acid RS](#) in *Mobile phase*. [NOTE—Sonication may be necessary for complete dissolution.]**Standard solution:** 0.02 mg/mL of [USP Fumaric Acid RS](#) in *Mobile phase***System suitability****Sample:** *Standard solution***Suitability requirements****Tailing factor:** NMT 2**Relative standard deviation:** NMT 2.0%**Analysis****Samples:** *Sample solution* and *Standard solution*

Calculate the percentage of fumaric acid content in the portion of Ibutilide Fumarate taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

 r_U = peak response of fumaric acid from the *Sample solution* r_S = peak response of fumaric acid from the *Standard solution* C_S = concentration of [USP Fumaric Acid RS](#) in the *Standard solution* (mg/mL) C_U = concentration of Ibutilide Fumarate in the *Sample solution* (mg/mL)**Acceptance criteria:** 12.7%–13.5%**• ORGANIC IMPURITIES****Solution A:** 2 mL/L of triethylamine in water. Adjust with perchloric acid to a pH of 2.5.**Solution B:** Acetonitrile**Diluent:** Acetonitrile and *Solution A* (40:60)**Mobile phase:** See [Table 1](#).**Table 1**

Time (min)	Solution A (%)	Solution B (%)
0	60	40
15	60	40
30	30	70
40	30	70
50	60	40
55	60	40

Standard solution: 2 µg/mL of [USP Ibutilide Fumarate RS](#) and 3 µg/mL each of [USP Ibutilide Related Compound A RS](#) and [USP Ibutilide Related Compound B RS](#) in *Diluent***Sample solution:** 2 mg/mL of Ibutilide Fumarate in *Diluent***Chromatographic system:** Proceed as directed in the Assay, except use a run time of NLT 2.5 times the retention time of ibutilide for the *Standard solution* and NLT 6.2 times the retention time of ibutilide for the *Sample solution*.**System suitability****Sample:** *Standard solution***Suitability requirements****Column efficiency:** NLT 5000 theoretical plates for the ibutilide peak**Relative standard deviation:** NMT 3.0% for the ibutilide peak**Analysis**

Samples: Standard solution and Sample solution

Calculate the percentage of ibutilide related compound A, ibutilide related compound B, and any unspecified impurity in the portion of Ibutilide Fumarate taken:

$$\text{Result} = (r_u/r_s) \times (C_s/C_u) \times 100$$

r_u = peak response of ibutilide related compound A, ibutilide related compound B, or any other unspecified impurity from the *Sample solution*

r_s = peak response of ibutilide related compound A, ibutilide related compound B, or ibutilide (for calculating any other unspecified impurity) from the *Standard solution*

C_s = concentration of [USP Ibutilide Related Compound A RS](#), [USP Ibutilide Related Compound B RS](#), or [USP Ibutilide Fumarate RS](#) (for calculating any unspecified impurity) in the *Standard solution* (mg/mL)

C_u = concentration of Ibutilide Fumarate in the *Sample solution* (mg/mL)

Acceptance criteria: See [Table 2](#). Disregard the fumaric acid peak and any peak less than 0.01%.

Table 2

Name	Relative Retention Time	Acceptance Criteria, NMT (%)
Fumaric acid ^a	0.33	—
Ibutilide	1.00	—
Ibutilide related compound B ^b	2.66	0.15
Ibutilide related compound A ^c	3.38	0.15
Any unspecified impurity	—	0.10
Total impurities	—	0.35

^a This impurity is controlled in the test for *Content of Fumaric Acid*.

^b N-Ethyl-N-heptyl-4-hydroxy-4-[4-(methylsulfonamido)phenyl]butanamide.

^c N-Ethyl-N-heptyl-4-[4-(methylsulfonamido)phenyl]-4-oxobutanamide.

SPECIFIC TESTS

- [WATER DETERMINATION, Method I \(921\)](#): NMT 1.0%

ADDITIONAL REQUIREMENTS

- **PACKAGING AND STORAGE:** Preserve in air-tight containers, and protect from light. Store at controlled room temperature.

[• USP REFERENCE STANDARDS \(11\)](#)

[USP Fumaric Acid RS](#)

[USP Ibutilide Fumarate RS](#)

[USP Ibutilide Related Compound A RS](#)

N-Ethyl-N-heptyl-4-[4-(methylsulfonamido)phenyl]-4-oxobutanamide.

$C_{20}H_{32}N_2O_4S$ 396.54

[USP Ibutilide Related Compound B RS](#)

N-Ethyl-N-heptyl-4-hydroxy-4-[4-(methylsulfonamido)phenyl]butanamide.

$C_{20}H_{34}N_2O_4S$ 398.56

Auxiliary Information - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
IBUTILIDE FUMARATE	Documentary Standards Support	SM22020 Small Molecules 2

Chromatographic Database Information: [Chromatographic Database](#)

Most Recently Appeared In:

Pharmacopeial Forum: Volume No. PF 39(4)

Current DocID: [GUID-E9494226-4AAE-4175-8102-61063DE91202_2_en-US](#)

DOI: https://doi.org/10.31003/USPNF_M39908_02_01

DOI ref: [fbs6d](#)

OFFICIAL